HALO has been the subject of several other reports. JMP Securities restated a buy rating and set a $21.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, February 27th. Cantor Fitzgerald reiterated a buy rating on shares of Halozyme Therapeutics in a research report on Wednesday, May 8th. Zacks Investment Research downgraded shares of Halozyme Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 30th. TheStreet downgraded shares of Halozyme Therapeutics from a c rating to a d rating in a research report on Tuesday, March 5th. Finally, ValuEngine downgraded shares of Halozyme Therapeutics from a buy rating to a hold rating in a research report on Wednesday, March 6th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of Hold and a consensus target price of $20.40.
HALO stock traded down $0.11 during trading hours on Wednesday, reaching $15.73. 615,135 shares of the stock were exchanged, compared to its average volume of 777,257. The stock has a market cap of $2.25 billion, a PE ratio of -28.09 and a beta of 1.77. The company has a current ratio of 2.95, a quick ratio of 2.72 and a debt-to-equity ratio of 0.07. Halozyme Therapeutics has a 12 month low of $13.24 and a 12 month high of $19.56.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. Halozyme Therapeutics had a negative return on equity of 20.36% and a negative net margin of 28.70%. The company had revenue of $56.95 million during the quarter, compared to analysts’ expectations of $67.80 million. During the same quarter last year, the company earned ($0.19) EPS. Halozyme Therapeutics’s revenue for the quarter was up 84.3% compared to the same quarter last year. On average, analysts forecast that Halozyme Therapeutics will post -0.42 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can raised its holdings in shares of Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 896 shares during the last quarter. Sageworth Trust Co grew its position in Halozyme Therapeutics by 4,200.0% in the 1st quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 2,100 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $140,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Halozyme Therapeutics by 33.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 2,430 shares during the period. Finally, Paloma Partners Management Co bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $150,000. Institutional investors own 82.08% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Story: What is the return on assets formula?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.